Drugs / CGM097
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01760525 | Mar 2013 → Jul 2020 | — | Novartis Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CGM097 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01760525 ↗ |
| Known as | NVP-CGM-097 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3601398 ↗ |
| Action | Inhibit | “CGM097 inhibits the p53-HDM2 interaction” PMID 34140638 ↗ Jun 2021 |
| Modality | Small molecule | — CHEMBL3601398 ↗ |
| Route | Oral | “received oral treatment with CGM097” PMID 34140638 ↗ Jun 2021 |
| Target | MDM2 | “CGM097 inhibits the p53-HDM2 interaction” PMID 34140638 ↗ Jun 2021 |